Evidence map›Paper›PMID 34986868›Full record

ArticleMicrobial cell factories2022

PglB function and glycosylation efficiency is temperature dependent when the pgl locus is integrated in the Escherichia coli chromosome.

Vanessa S Terra, Marta Mauri, Thippeswamy H Sannasiddappa, Alexander A Smith, Mark P Stevens, Andrew J Grant, Brendan W Wren, Jon Cuccui, Glycoengineering of Veterinary Vaccines consortium (GoVV)

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Alpha-N-acetylgalactosaminidase in cancer: diagnostic applications and related treatment strategies.International journal of physiology, pathophysiology and pharmacology · 2025
    Review
  2. Construction of anFrontiers in bioengineering and biotechnology · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Vanessa S TerraLondon School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E7HT, UK.ORCID http://orcid.org/0000-0002-2734-4036
Marta MauriLondon School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E7HT, UK.
Thippeswamy H SannasiddappaDepartment of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, CB3 0ES, Cambridgeshire, UK.
Alexander A SmithDepartment of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, CB3 0ES, Cambridgeshire, UK.
Mark P StevensThe Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, EH25 9RG, UK.
Andrew J GrantDepartment of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, CB3 0ES, Cambridgeshire, UK.
Brendan W WrenLondon School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E7HT, UK. Brendan.Wren@lshtm.ac.uk.
Jon CuccuiLondon School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E7HT, UK. Jon.Cuccui@lshtm.ac.uk.
Glycoengineering of Veterinary Vaccines consortium (GoVV)
University of London · GBUniversity of Cambridge · GBRoslin Institute · GB

Funding

Biotechnology and Biological Sciences Research Council BB/F009321/1Biotechnology and Biological Sciences Research Council BB/N001591/1
6 · The paper itself

Abstract

backgroundCampylobacter is an animal and zoonotic pathogen of global importance, and a pressing need exists for effective vaccines, including those that make use of conserved polysaccharide antigens. To this end, we adapted Protein Glycan Coupling Technology (PGCT) to develop a versatile Escherichia coli strain capable of generating multiple glycoconjugate vaccine candidates against Campylobacter jejuni.

resultsWe generated a glycoengineering E. coli strain containing the conserved C. jejuni heptasaccharide coding region integrated in its chromosome as a model glycan. This methodology confers three advantages: (i) reduction of plasmids and antibiotic markers used for PGCT, (ii) swift generation of many glycan-protein combinations and consequent rapid identification of the most antigenic proteins or peptides, and (iii) increased genetic stability of the polysaccharide coding-region. In this study, by using the model glycan expressing strain, we were able to test proteins from C. jejuni, Pseudomonas aeruginosa (both Gram-negative), and Clostridium perfringens (Gram-positive) as acceptors. Using this pgl integrant E. coli strain, four glycoconjugates were readily generated. Two glycoconjugates, where both protein and glycan are from C. jejuni (double-hit vaccines), and two glycoconjugates, where the glycan antigen is conjugated to a detoxified toxin from a different pathogen (single-hit vaccines). Because the downstream application of Live Attenuated Vaccine Strains (LAVS) against C. jejuni is to be used in poultry, which have a higher body temperature of 42 °C, we investigated the effect of temperature on protein expression and glycosylation in the E. coli pgl integrant strain.

conclusionsWe determined that glycosylation is temperature dependent and that for the combination of heptasaccharide and carriers used in this study, the level of PglB available for glycosylation is a step limiting factor in the glycosylation reaction. We also demonstrated that temperature affects the ability of PglB to glycosylate its substrates in an in vitro glycosylation assay independent of its transcriptional level.

Indexed as

TemperatureBacterial ProteinsBacterial VaccinesCampylobacter jejuniChromosomesEscherichia coliGlycoconjugatesGlycosylationMembrane ProteinsMetabolic EngineeringPolysaccharides, BacterialBacterial ProteinsBacterial VaccinesGlycoconjugatesMembrane ProteinsPolysaccharides, BacterialBiological conjugationOne healthPGCTPglBPoultryTemperatureVaccine

Identifiers

PMID34986868
PMCPMC8728485
OpenAlexW4205318400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.